Aspira Pathlab & Diagnostics Receives Open Offer for 26% Stake at Rs. 55 Per Share

Aspira Pathlab & Diagnostics Limited has announced a significant development that could potentially reshape its ownership structure. Five acquirers, along with a person acting in concert (PAC), have made an open offer to acquire a substantial stake in the company.

Open Offer Details

The open offer, announced on September 26, 2025, aims to acquire 26,76,180 equity shares, representing 26.00% of Aspira Pathlab & Diagnostics Limited's total paid-up equity shares. The offer price has been set at Rs. 55.00 per share, presenting an opportunity for existing shareholders to potentially realize value from their investments.

The acquirers involved in this open offer are:

1. Arvind Karsandas Bhanushali
2. Deepali Arvind Bhanushali
3. Jay Arvind Bhanushali
4. Nikunj Velji Mange
5. Raj Arvind Bhanushali

Additionally, Shraddha Nikunj Mange is acting in concert with the acquirers in this offer.

Regulatory Compliance

The open offer is being made in compliance with the Securities and Exchange Board of India (SEBI) Substantial Acquisition of Shares and Takeovers Regulations, 2011. This move ensures transparency and protects the interests of all shareholders.

Company Background

Aspira Pathlab & Diagnostics Limited, established in 1973, is positioned as India's first fully integrated lab. The company has been expanding its footprint, with recent data indicating a presence of over 600 centers across India. In the fiscal year 2024-25, Aspira added 91 new locations to its network, showcasing its growth trajectory.

Financial Performance

During the company's recent 52nd Annual General Meeting, it was reported that Aspira Pathlab & Diagnostics Limited achieved a profit of Rs. 2.07 crores for the fiscal year, marking a significant turnaround from a net loss of Rs. 2.60 crores in the previous year. This improved financial performance could be a factor in the timing of the open offer.

Market Implications

The open offer at Rs. 55.00 per share signals the acquirers' confidence in the company's value and future prospects. For existing shareholders, this offer presents a decision point – whether to tender their shares at the offered price or to retain their stake in anticipation of future growth.

Conclusion

As Aspira Pathlab & Diagnostics Limited faces this potential ownership change, stakeholders will be closely watching how this development unfolds. The success of this open offer could lead to a shift in the company's strategic direction and governance structure. Shareholders are advised to carefully consider the offer in light of the company's recent performance and future growth prospects.

The market will be keenly observing the response to this open offer and its potential impact on Aspira Pathlab & Diagnostics Limited's future in the competitive healthcare diagnostics sector.